ACADIA Pharmaceuticals Inc

Healthcare · Biotechnology

22.20$ -12.8% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

ACADIA Pharmaceuticals Inc (ACAD) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 308 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ACAD
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	5.3	12	15	30	36	44	49	57	58	60	63	83	95	98	90	110	121	121	107	115	132	131	115	135	131	136	118	165	212	231	206	242	250	260	244	265	279	284	268	308	1,139
Cost of Revenue	1.3	2.3	2.9	3.2	3.2	3.7	3.5	5.1	5.4	4.4	4.6	5.0	4.7	5.3	5.0	5.5	4.8	5.3	4.7	5.2	6.7	2.6	3.0	2.7	2.1	2.4	1.7	7.5	15	18	23	18	19	22	20	21	22	26	25	28	101
Gross Profit	3.9	9.7	12	27	32	40	45	52	53	55	58	78	90	93	85	105	116	116	102	110	125	128	113	132	129	134	117	158	197	213	183	224	232	238	224	244	257	258	243	280	1,038
Research & Development	26	30	35	34	36	43	39	47	53	48	53	67	63	58	73	64	120	62	57	57	59	67	129	76	81	76	69	59	157	67	60	76	67	101	78	78	88	85	77	82	331
Selling, General & Administrative	51	58	66	62	62	51	61	69	61	34	93	68	73	92	102	84	82	70	112	97	82	97	97	90	78	99	101	96	98	102	108	117	133	130	126	134	133	156	171	160	620
Total Operating Expenses	76	88	101	96	99	110	100	116	114	122	146	135	135	149	175	149	202	183	169	154	140	173	226	166	159	180	170	155	255	178	168	193	200	84	205	211	221	240	248	242	951
Operating Income	-72	-78	-89	-68	-66	-70	-55	-64	-61	-67	-88	-57	-45	-56	-90	-44	-86	-67	-67	-44	-15	-45	-113	-34	-31	-46	-54	3.0	-58	35	15	30	32	154	19	32	36	17	-4.6	38	86
Interest Expense	0.8	0.9	1.0	1.0	1.1	1.1	1.2	1.3	1.2	1.7	2.9	2.5	2.4	3.3	3.0	1.8	1.2	0.6	0.2	0.1	0.1	0.1	0.1	0.6	2.3	3.6	9.1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pre-Tax Income	-72	-77	-88	-67	-65	-69	-54	-63	-62	-65	-85	-55	-42	-53	-88	-42	-85	-66	-66	-43	-15	-43	-113	-34	-26	-41	-45	6.3	-52	40	21	37	39	161	28	40	45	26	4.0	46	121
Income Tax Expense	0.0	1.3	0.1	0.4	0.7	0.0	0.6	0.2	0.4	0.0	0.4	0.4	-0.3	0.4	-3.7	0.4	-0.2	0.4	0.0	0.5	-0.3	0.2	0.5	0.4	0.8	0.8	-1.9	5.2	13	-6.1	4.4	3.8	6.0	17	8.8	14	-27	-247	0.3	15	-259
Net Income	-72	-79	-88	-67	-65	-69	-54	-63	-62	-65	-85	-55	-42	-53	-88	-42	-85	-67	-66	-44	-14	-43	-113	-34	-27	-42	-43	1.1	-65	46	17	33	33	144	19	27	72	274	3.6	32	380
EBITDA	-72	-78	-88	-67	-65	-68	-54	-63	-61	-66	-87	-56	-45	-56	-89	-43	-85	-66	-66	-42	-14	-42	-112	-33	-26	-40	-45	8.1	-50	41	27	40	41	12	31	43	48	29	7.0	32	116

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings